Pharmaceutical giant Mylan was at the center of criticism last year over rising drug prices. Its EpiPen became the lightning rod for scrutiny, as the life-saving allergy drug's price increased by nearly 500 percent over seven years. In her first in-depth interview since giving testimony before Congress, Mylan CEO Heather Bresch talks to Norah O'Donnell and responds to the outrage among lawmakers and consumers.
